The abstract is read at the publisher; the summary is JClub's.
Semaglutide lowered time to first major kidney composite events versus placebo in pooled SELECT, FLOW, and SOUL participants (N=30 787; HR 0·84, 95% CI 0·77–0·91).
- Why it matters: People with cardio-kidney-metabolic disease still face substantial kidney risk, and evidence across multiple large trials needed a prespecified participant-level pooled assessment.
- What they did: In prespecified analyses of three randomized, placebo-controlled phase 3 trials, participants received semaglutide (1·0 mg weekly in FLOW, 2·4 mg weekly in SELECT, 14 mg daily oral in SOUL) plus standard of care, and the pooled primary endpoint was time to first kidney composite event.
- The result: Semaglutide produced 973 first events of the primary kidney composite versus 1134 with placebo, and also reduced a narrower kidney composite (347 vs 416; HR 0·80, 95% CI 0·69–0·92) with overall similar safety.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.